eClinical Solutions LLC, a global provider of digital clinical software and services, today announced Everest Group has recognized eClinical Solutions as the highest-designated Leader in Life Sciences Clinical Data and Analytics Platforms in the report, “Life Sciences Clinical Data and Analytics (D&A) Platforms PEAK Matrix® Assessment 2024.” The proprietary framework assesses 18 clinical D&A platform providers across eight subdimensions related to market impact, as well as vision and capability. This placement reinforces the power of the elluminate Clinical Data Cloud® platform to democratize clinical and operations data from ingestion through submission, increasing clinical development productivity and reducing cycle times for life sciences organizations of all sizes.

“In recent years we have seen the data technology needs of biopharma companies intensify, fueled by growing trial complexity and tech fragmentation. When we founded eClinical Solutions twelve years ago, we anticipated these challenges and pioneered the clinical data and analytics platform category when we created elluminate,” said Raj Indupuri, co-founder and chief executive officer, eClinical Solutions. “We are honored that Everest Group named us in the highest Leader position in this year’s PEAK Matrix. This recognition affirms our ability to solve the industry’s evolving clinical data needs at a critical inflection point when cycle time has become the new currency. We will continue to innovate our technology and services to help biopharma optimize processes and remain future-ready with AI/ML, unlock the full value of their data, and bring medicines to patients faster.”

eClinical Solutions’ strengths highlighted within the assessment include:

 

• Robust data integration capabilities, enabling the platform to ingest data from multiple data collection systems;
• Platform’s ease of deployment, flexibility, and scalability, along with ease of use and User Interface (UI);
• Increasing focus on multiple AI and generative AI use cases, including automated data mapping, data classification, anomaly detection, and conversational analytics;
• Comprehensiveness of the elluminate platform, with end-to-end capabilities across the clinical data value chain; and
• Leveraging of a comprehensive partnership ecosystem with various categories of partner firms including Real-World Data (RWD), Electronic Data Capture (EDC), electronic Trial Master File (eTMF) providers, system integrators, consulting firms, and Decentralized Clinical Trials (DCT) platform providers.

“The increasing complexity of clinical trials, driven by data proliferation and the rise of decentralized and hybrid trial designs, is prompting sponsors to adopt unified clinical data and analytics platforms for effective data management and informed decision-making. In response, platform providers are enhancing their end-to-end data and analytics capabilities, while incorporating AI and generative AI use cases throughout the data and analytics value chain to automate routine tasks, generate insights, and strengthen quality and risk management,” says Nisarg Shah, Practice Director at Everest Group. “eClinical Solutions offers a scalable, flexible, easily deployable, and user-friendly platform. The platform showcases robust end-to-end clinical data and analytics capabilities, including strong data integration. These capabilities, complemented by an extensive partnership ecosystem, have helped eClinical Solutions earn a Leader position in Everest Group’s Life Sciences Clinical Data and Analytics (D&A) Platforms PEAK Matrix® Assessment 2024."

The assessment’s vision and capability dimension measures companies’ ability to deliver products successfully, which is determined through five subdimensions: vision and strategy, technology capability, flexibility and ease of deployment, engagement and commercial model, and support. eClinical Solutions holds the highest position of Leaders in the first four subdimensions. eClinical Solutions also holds the highest position of Leaders in the three subdimensions of the market impact dimension: market adoption, portfolio mix, and value delivered.

eClinical was also named a Leader in the inaugural Life Sciences Clinical Data and Analytics (D&A) Platforms PEAK Matrix® Assessment in 2023. This year’s accolade comes on the heels of GI Partners’ majority investment in eClinical Solutions, signaling continued business growth and enabling product expansion at scale. This includes further incorporating pervasive AI across the company’s offerings to increase efficiencies, decrease manual work, and ultimately deepen the company’s impact, vision, and capabilities for the industry at large.

For more information on eClinical Solutions’ innovative elluminate platform, please visit: www.eclinicalsol.com/platform.

To read the full Everest Group PEAK Matrix Assessment, please visit: https://www.eclinicalsol.com/analyst-reports/everest-group-life-sciences-assessment-2024/.